Observational Study in Japanese Type 2 Diabetes Patients (INSIGHTS)

• Summarize by occurrence the reason for insulin treatment change at study entry [ Time Frame: Baseline ] [ Designated as safety issue: No ]
• Change in HbA1c at baseline and 12 weeks after a significant change in insulin treatment regimen [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
• Change in treatment adherence at baseline and 12 weeks after a significant change in insulin treatment regimen [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
• Change in DTSQ (Diabetes treatment satisfaction questionnaire) at baseline and 12 weeks after a significant change in insulin treatment regimen [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
• Total daily dose of insulin [ Time Frame: Baseline, over 12 weeks ] [ Designated as safety issue: No ]
• Change in type of insulin product [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
• Change from baseline in use of concomitant oral hypoglycemic drugs [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]

This study is designed to address the gap in the literature related to changing treatment regimen or formulation between different types of insulin, and how this change impacts quality of life, adherence, individual patient treatment satisfaction and glycemic control.

To measure changes in Health Related Quality of Life (as measured by the Insulin Therapy Related-Quality of Life: ITR-QOL) in insulin treated type 2 diabetes over a 12 weeks period following a significant change in insulin treatment regimen. Definition of significant change is a) increase or decrease the in number of injections per day, or/and b) change in formulation of insulin (human or analog insulin, basal or bolus, rapid or mix insulin), and/or c) change in administration method (syringe or pen, disposal or re-usable).

Japanese patients with type 2 diabetes who are treated with insulin and about to have significant treatment change.

Inclusion Criteria:

• Inpatients or outpatients with type 2 diabetes, aged 20 years or older, on insulin therapy who have planned to change insulin therapy during the registration period of the study
• Patients who have provided written informed consent to participation in the study after receiving explanations about the objective and other details of the study
• Patients who have received the same insulin therapy for 3 months or longer before informed consent. (i.e. receiving the same type of insulin preparation at the same dosing frequency regardless of insulin dose)

Exclusion Criteria:

• Patients who have planned to discontinue insulin therapy
• Patients incapable of completing the ITR-QOL, DTSQ and patient's questionnaire based on their self-ratings
• Patients with type 1 diabetes
• Patients who have used CSII or have planned to switch to CSII(continuous subcutaneous insulin infusion )
• Patients with poor treatment compliance as determined by their investigators based on the treatment history